Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice

Diabetologia

Volumn 54, Issue 8, 2011, Pages 2132-2142

  Kiefer, F W ^a   Neschen, S ^b   Pfau, B ^a   Legerer, B ^a   Neuhofer, A ^a   Kahle, M ^b   Hrabe De Angelis M ^b   Schlederer, M ^c   Mair, M ^c   Kenner, L ^c   Plutzky, J ^d   Zeyda, M ^a   Stulnig, T M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Gluconeogenesis; High fat diet; Inflammation; Insulin resistance; Non alcoholic fatty liver disease

Indexed keywords

INSULIN RECEPTOR SUBSTRATE 2; NEUTRAL INSULIN; OSTEOPONTIN; RECOMBINANT HUMAN INSULIN; TRANSCRIPTION FACTOR FKHR; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG ACTIVITY; FATTY LIVER; GENE TARGETING; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HYPERINSULINEMIA; INFLAMMATION; INSULIN RESISTANCE; KNOCKOUT GENE; LIPID DIET; LIPID STORAGE; LIPOGENESIS; LOW FAT DIET; MACROPHAGE; MALE; MOUSE; NONHUMAN; OBESITY; OPN GENE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; FATTY LIVER; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; MICE; MICE, KNOCKOUT; OBESITY; OSTEOPONTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRIGLYCERIDES;

EID: 79960901954     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2170-0     Document Type: Article

References (46)

1. Kopelman PG (2000) Obesity as a medical problem. Nature 404:635-643 (Pubitemid 30205068)
2. Marchesini G, Bugianesi E, Forlani G et al (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917-923 (Pubitemid 36397405)
3. Berk PD (2008) Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome. Hepatology 48:1362-1376
4. den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA (2004) Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol 24:644-649 (Pubitemid 38451598)
5. Fabbrini E, Sullivan S, Klein S (20100 Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51:679-689
6. Korenblat KM, Fabbrini E, Mohammed BS, Klein S (2008) Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 134:1369-1375 (Pubitemid 351615354)
7. Postic C, Girard J (2008) Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118:829-838 (Pubitemid 351364588)
8. Lefkowitch JH, Haythe JH, Regent N (2002) Kupffer cell aggregation and perivenular distribution in steatohepatitis. Mod Pathol 15:699-704 (Pubitemid 34787304)
9. Cai D, Yuan M, Frantz DF et al (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11:183-190 (Pubitemid 40321354)
10. Kolak M, Westerbacka J, Velagapudi VR et al (2007) Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 56:1960-1968 (Pubitemid 47195815)
11. Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ (2009) Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm 2009:831670
12. Lanthier N, Molendi-Coste O, Horsmans Y, van Rooijen N, Cani PD, Leclercq IA (2009) Kupffer cell activation is a causal factor for hepatic insulin resistance. Am J Physiol Gastrointest Liver Physiol 298:G107-G116
13. Obstfeld AE, Sugaru E, Thearle M et al (2010) CCR2 regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes 59:916-925
14. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J (2002) Osteopontin - a molecule for all seasons. QJM 95:3-13
15. Standal T, Borset M, Sundan A (2004) Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26:179-184
16. Xu G, Sun W, He D et al (2005) Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated with joint inflammation, not with genetic polymorphism. J Rheumatol 32:410-416 (Pubitemid 40381409)
17. Gomez-Ambrosi J, Catalan V, Ramirez B et al (2007) Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab 92:3719-3727 (Pubitemid 47435361)
18. Kiefer FW, Zeyda M, Todoric J et al (2008) Osteopontin expression in human and murine obesity: extensive local upregulation in adipose tissue but minimal systemic alterations. Endocrinology 149:1350-1357 (Pubitemid 351397930)
19. Kiefer FW, Zeyda M, Gollinger K et al (2010) Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes 59:935-946
20. Nomiyama T, Perez-Tilve D, Ogawa D et al (2007) Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest 117:2877-2888 (Pubitemid 47529618)
21. Bertola A, Deveaux V, Bonnafous S et al (2009) Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes 58:125-133
22. Sahai A, Malladi P, Melin-Aldana H, Green RM, Whitington PF (2004) Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am J Physiol Gastrointest Liver Physiol 287:G264-G273 (Pubitemid 38802141)
23. Sahai A, Malladi P, Pan X et al (2004) Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 287:G1035-G1043 (Pubitemid 39423696)
24. Kwon HJ, Won YS, Yoon WK, Nam KH, Kim DY, Kim HC (2010) The role of osteopontin in d-galactosamine-induced liver injury in genetically obese mice. Toxicol Appl Pharmacol 242:344-351
25. Neschen S, Morino K, Dong J et al (2007) n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-alpha- dependent manner. Diabetes 56:1034-1041 (Pubitemid 46525082)
26. Neschen S, Morino K, Hammond LE et al (2005) Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn- 3-phosphate acyltransferase 1 knockout mice. Cell Metab 2:55-65 (Pubitemid 43239825)
27. Haemmerle G, Zimmermann R, Strauss JG et al (2002) Hormone-sensitive lipase deficiency inmice changes the plasma lipid profile by affecting the tissue-specific expression pattern of lipoprotein lipase in adipose tissue and muscle. J Biol Chem 277:12946-12952 (Pubitemid 34952662)
28. Zeyda M, Saemann MD, Stuhlmeier KM et al (2005) Polyunsaturated fatty acids block dendritic cell activation and function independently of NF-kappaB activation. J Biol Chem 280:14293-14301 (Pubitemid 40517332)
29. Kim JB, Wright HM, Wright M, Spiegelman BM (1998) ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci U S A 95:4333-4337 (Pubitemid 28207912)
30. Yen CL, Stone SJ, Koliwad S, Harris C, Farese RV Jr (2008) Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. J Lipid Res 49:2283-2301
31. Morino K, Petersen KF, Shulman GI (2006) Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 55(Suppl 2):S9-S15 (Pubitemid 44927027)
32. Dong XC, Copps KD, Guo S et al (2008) Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab 8:65-76 (Pubitemid 351863393)
33. Puigserver P, Spiegelman BM (2003) Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha PGC-1 alpha: transcriptional coactivator and metabolic regulator. Endocr Rev 24:78-90 (Pubitemid 36223280)
34. Baffy G (2009) Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol 51:212-223
35. Murano I, Barbatelli G, Parisani V et al (2008) Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J Lipid Res 49:1562-1568
36. de Taeye BM, Novitskaya T, McGuinness OP et al (2007) Macrophage TNF-alpha contributes to insulin resistance and hepatic steatosis in diet-induced obesity. Am J Physiol Endocrinol Metab 293:E713-E725 (Pubitemid 47358983)
37. Qureshi K, Abrams GA (2007) Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 13:3540-3553 (Pubitemid 47162261)
38. Seki E, de Minicis S, Osterreicher CH et al (2007) TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 13:1324-1332 (Pubitemid 350073596)
39. Ramaiah SK, Rittling S (2008) Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci 103:4-13 (Pubitemid 351524472)
40. Zeyda M, Stulnig TM (2007) Adipose tissue macrophages. Immunol Lett 112:61-67 (Pubitemid 47379852)
41. Stienstra R, Saudale F, Duval C et al (2010) Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology 51:511-522
42. Huang W, Metlakunta A, Dedousis N et al (2010) Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes 59:347-357
43. Kanda H, Tateya S, Tamori Y et al (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116:1494-1505
44. Baggiolini M (1998) Chemokines and leukocyte traffic. Nature 392:565-568 (Pubitemid 28207705)
45. Diao H, Kon S, Iwabuchi K et al (2004) Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 21:539-550 (Pubitemid 39370509)
46. Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH (2010) Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 53:106-115